FBR Board of Directors
|Claire Pomeroy, MD, MBA – president, Albert and Mary Lasker Foundation, Chair of the Board of Directors of the Foundation for Biomedical Research
At the Lasker Foundation, Dr. Pomeroy oversees the Lasker Awards program, as well as education and outreach initiatives with the mission of increasing support for biomedical research. An expert in infectious diseases, Dr. Pomeroy is a long-time advocate for public health and patients, especially those with HIV/AIDS. She serves on the boards of Becton Dickinson and Company, New York Academy of Medicine, Sierra Health Foundation and New York Blood Center, and is a trustee for Morehouse School of Medicine.
|Henry S. Friedman, MD – James P. Powell, Jr. Professor of Pediatric Oncology; professor of neurosurgery; assistant professor of pathology; associate professor of medicine; professor of pediatrics at Duke University School of Medicine, Vice Chair of the Board of Directors of the Foundation for Biomedical Research
Dr. Friedman is an academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University. The author of more than 500 peer-reviewed articles, reviews, and book chapters, Dr. Friedman’s laboratory work involves the study of adult and child central nervous system malignancies with athymic nude mice and rats.
|James S. Allan, M.D., M.B.A. - associate professor of surgery, Division of Thoracic Surgery; co-director of Cardiothoracic Transplantation Laboratory ; chair of Institutional Animal Care and Use Committee; Massachusetts General Hospital & Harvard Medical School
Dr. Allan is a thoracic surgeon whose clinical interests include the surgical management of benign and malignant diseases of the lungs and esophagus. His research interests involve transplantation tolerance and xenotransplantation as studied in large animal models.
|Lenore Cooney – communications consultant at LCooney Consulting
Ms. Cooney’s present and former consultancy practices have served the strategic communications needs of clients in health care, disease prevention, nutrition, pharmaceuticals, biotechnology, and health advocacy in the U.S. and internationally. She has also managed educational and product marketing projects in health and medicine.
|Elton Greig – director, corporate affairs at Amgen
Mr. Greig is responsible for enterprise and executive communications. He supports the CEO's internal and external communications, including the development and refinement of key messages, talking points and presentations.
|Atul Grover, MD, PhD – executive vice president, Association of American Medical Colleges (AAMC)
At AAMC, Dr. Grover provides strategic leadership in the areas of medical education, academic affairs, health care affairs, scientific affairs, learning and leadership programming, diversity and inclusion, public policy, and communications. Dr. Grover holds faculty appointments at the George Washington University (GWU) School of Medicine, where he earned his MD, and at the Johns Hopkins University Bloomberg School of Public Health, where he earned his PhD.
|David Korn, MD – (B.A., scl, M.D., cl, Harvard University) is Consultant in Pathology at the Massachusetts General Hospital and Professor of Pathology at Harvard Medical School.
Dr. Korn is presently Consultant in Pathology at MGH and Professor of Pathology at Harvard Medical School. During his career, he has served as Inaugural Vice-Provost for Research, Harvard University; Senior Vice President and Chief Scientific Officer, Association of American Medical Colleges; Professor and Founding C hair of Pathology, then Dean of Medicine and VP of Stanford University. From 1984-91, he was Chair of the National Cancer Advisory Board, a Presidential appointment. He has authored more than 150 publications.
|Joanne Kurtzberg, MD – chief scientific officer, Robertson Clinical and Translational Cell Therapy Program; Jerome S. Harris Professor of Pediatrics at Duke University Medical Center
Dr. Kurtzberg expert in pediatric hematology/oncology, pediatric blood and marrow transplantation, umbilical cord blood banking and transplantation, and novel applications of cord blood in the emerging fields of cellular therapies and regenerative medicine. She has published more than 300 peer-reviewed papers, chapters, and scientific reviews.
|John E. Niederhuber, MD – CEO, Inova Health System, Inova Translational Medicine Institute
As founder and leader of the ITMI, Dr. Niederhuber directs a program that integrates technical innovation, informatics, and sophisticated genomic analyses with the goal of managing disease risk and delivering excellence in individualized (personalized) healthcare, research, and education. He was formerly the director of the National Cancer Institute.
|Arthur H. Rubenstein, MBBCh – professor of medicine, Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania
Dr. Rubenstein is an endocrinologist recognized for clinical expertise and groundbreaking research in diabetes. He was previously dean of the University of Pennsylvania Health System. Dr. Rubenstein has authored more than 350 publications, served in editorial advisory positions for academic journals, and chaired numerous national scientific and medical organizations.
|Carol Scheman, MSSA – independent non-profit organization management professional
As an independent consultant, Ms. Scheman has worked with the federal government, research universities, and scientific societies. She previously was vice president of the Association of American Universities and was the first woman appointed deputy commissioner of the Food and Drug Administration (FDA).
|Oswald Steward, PhD – director, Reeve-Irvine Research Center for Spinal Cord Injury; senior associate dean for research; professor of neurobiology and behavior, University of California, Irvine School of Medicine
Dr. Steward is known for his research on how nerve cells create and maintain their connections with each other, and how these synapses are modified after injury. He has also conducted research on how genes influence nerve cell regeneration, growth and function, and how physiological activity affects nerve cell connections.
FBR Board of Advisors
|Irv Weissman, MD – director, Ludwig Center for Stem Cell Research; Virginia and D.K. Ludwig Professor for Clinical Investigation in Cancer Research at Stanford University
Dr. Weissman is an expert in the fields of hematopoiesis, leukemia, and hematopoietic stem cells (HSC). His laboratory, the first to identify and isolate the blood-forming stem cell (HSC) from mice, is also distinguished for the discovery of the human HSC, a human brain-forming stem cell population, as well as skeletal muscle stem cells and an osteochondral stem cell in mice.
|Elias Zerhouni, MD – president, global research and development, Sanofi (retired); professor of radiology and biomedical engineering, Johns Hopkins University and Hospital
Dr. Zerhouni is an Algerian-born American physician, scientist, radiologist, inventor, entrepreneur, and biomedical engineer. He was appointed director of the National Institutes of Health in 2002, and is currently a senior fellow of the Bill and Melinda Gates Foundations. Dr. Zerhouni authored more than 200 publications, holds eight patents, and has founded or co-founded 5 start-up companies.
|Andrew L. Warshaw, MD, FACS, FRCSEd – W. Gerald Austen Professor of Surgery, Harvard Medical School; surgeon-in-chief, chairman, emeritus, Department of Surgery at Massachusetts General Hospital, director, Andrew L. Warshaw, MD, Institute for Pancreatic Cancer
Dr. Warshaw is an eminent researcher and surgeon who has made important contributions in the study of pancreatic cancer. His bibliography lists 385 original reports as well as 250 book chapters, reviews, and monographs and 13 books. The editor-in-chief of the journal SURGERY. Dr. Warshaw has also served as president of numerous national scientific and medical organizations.
|James Greenwood – president, Biotechnology Industry Orgnaization (BIO)
Mr. Greenwood is president and CEO of Biotechnology Industry Organization (BIO), which represents more than 1,200 U.S. and internationally-based biotechnology companies, academic institutions, state biotech centers, and related organizations. BIO members are involved in research and development of healthcare, agricultural, industrial, and environmental biotechnology products.